<div id="readability-page-1"><p>Wellington Shields Capital Management LLC acquired a new stake in  Insmed, Inc. (NASDAQ:INSM - Free Report) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund acquired 8,472 shares of the biopharmaceutical company's stock, valued at approximately $1,220,000.</p><ul><li>Russell Rebalance: 3 Stocks Ready to Move Higher</li></ul><p>Several other institutional investors and hedge funds have also bought and sold shares of the stock. Wellington Shields &amp; Co. LLC acquired a new stake in  Insmed in the third quarter worth $569,000.  Bessemer Group Inc. grew its stake in shares of  Insmed by 137.5% in the 3rd quarter. Bessemer Group Inc. now owns 836 shares of the biopharmaceutical company's stock valued at $121,000 after buying an additional 484 shares during the period.  SBI Securities Co. Ltd. increased its position in  Insmed by 404.9% in the 3rd quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company's stock valued at $30,000 after buying an additional 166 shares in the last quarter.  Savant Capital LLC increased its position in  Insmed by 36.7% in the 3rd quarter. Savant Capital LLC now owns 2,783 shares of the biopharmaceutical company's stock valued at $401,000 after buying an additional 747 shares in the last quarter.  Finally, Bridges Investment Management Inc. bought a new position in  Insmed in the third quarter worth approximately $221,000. </p><h2>Analysts Set New Price Targets</h2><p>INSM has been the subject of several recent research reports. Barclays started coverage on Insmed in a report on Tuesday, January 27th. They set an &#34;overweight&#34; rating and a $231.00 price objective for the company. HC Wainwright decreased their price target on shares of Insmed from $240.00 to $230.00 and set a &#34;buy&#34; rating for the company in a research note on Thursday, December 18th. UBS Group dropped their price objective on shares of Insmed from $223.00 to $215.00 and set a &#34;buy&#34; rating on the stock in a research note on Tuesday, January 6th. Wells Fargo &amp; Company  set a $195.00 target price on shares of Insmed in a research report on Thursday, December 18th. Finally, Cantor Fitzgerald upped their target price on shares of Insmed from $216.00 to $230.00 and gave the stock an &#34;overweight&#34; rating in a report on Tuesday, December 16th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, one  has assigned  a Hold rating and one  has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of &#34;Buy&#34; and an average target price of $203.45.</p><ul><li>Stock Rotation is Underway: Here are the Winners Moving Forward</li></ul><p><b>Read Our Latest Stock Report on INSM</b></p><h2>Insmed Stock Performance</h2><p>NASDAQ INSM opened at $149.86 on Friday. The company has a fifty day moving average price of $174.90 and a 200-day moving average price of $159.93. The firm has a market cap of $31.96 billion, a price-to-earnings ratio of -24.21 and a beta of 1.11. The company has a debt-to-equity ratio of 0.59, a current ratio of 4.63 and a quick ratio of 4.34. Insmed, Inc. has a 1 year low of $60.40 and a 1 year high of $212.75. </p><h2>Insiders Place Their Bets</h2><p>In other news, insider Michael Alexander Smith sold 640 shares of the firm's stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $156.27, for a total transaction of $100,012.80. Following the completion of the sale, the insider directly owned 56,397 shares of the company's stock, valued at $8,813,159.19. This trade represents a 1.12% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Sara Bonstein sold 748 shares of Insmed stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $156.34, for a total value of $116,942.32. Following the sale, the chief financial officer owned 79,758 shares in the company, valued at $12,469,365.72. The trade was a 0.93% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 274,857 shares of company stock valued at $50,121,247. Insiders own  3.00% of the company's stock. </p><h2>Insmed Company Profile</h2> (Free Report)<p>Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.  </p><p>The company's principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Insmed</li><li>NEW LAW: Congress Approves Setup For Digital Dollar?</li><li>The day the gold market broke</li><li>What a Former CIA Agent Knows About the Coming Collapse</li><li>Your Bank Account Is No Longer Safe</li><li>He just nailed another gold prediction …</li></ul><p><strong>Want to see what other hedge funds are holding INSM?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insmed, Inc. (NASDAQ:INSM - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU5TTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU5TTQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Insmed Right Now?</h2><p>Before you consider Insmed, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insmed wasn't on the list.</p><p>While Insmed currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ARKG

<p>Wellington Shields Capital Management LLC invested $1.22 million in Insmed, Inc. by acquiring 8,472 shares in the 3rd quarter. Other institutional investors also increased their stakes in the biopharmaceutical company. Analysts have set various price targets for Insmed, with a consensus rating of "Buy" and an average target price of $203.45. Insmed's stock performance shows a market cap of $31.96 billion and a price-to-earnings ratio of -24.21. Recent insider sales were reported, with insiders owning 3.00% of the company's stock.</p>

Market Beat

Proshares Ultra Nasdaq Biotech

Ark Genomic Revolution ETF

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

Health Care Select Sector SPDR

VG Health

BNY Mellon Innovators ETF

iShares US Pharma

VanEck Biotech ETF

Invesco Dorsey Wright Healthcare Momentum ETF

Insmed

ALPS Medical Breakthrough

iShares Biotechnology ETF

iShares Global Healthcare

Wellington Shields Capital Management LLC Invests $1.22 Million in Insmed, Inc. $INSM